RecruitingPhase 1NCT07815561

Phase 1 Study Involving SAB01 and Healthy Participants

A Phase 1, Randomized, Double Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of SAB01 in Healthy Participants

Sponsor

Santa Ana Bio

Enrollment

88 participants

Start Date

Aug 31, 2026

Study Type

INTERVENTIONAL

Conditions

healthy adult participants

Summary

SAB01 is an investigational bispecific monoclonal antibody targeting mast cells. This first-in-human Phase 1 clinical trial evaluates the safety, pharmacokinetics, and pharmacodynamics of single ascending doses of SAB01 in healthy adult participants.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Intravenous (IV) infusion of SAB01, a drug called Placebo IV Infusion, and others for people with healthy adult participants. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSubcutaneous (SC) single dose of SAB01

Single-dose administration of SAB01 by SC administration.

DRUGIntravenous (IV) infusion of SAB01

Intravenous doses of SAB01 via IV infusion.

DRUGPlacebo SC

Single-dose of placebo by subcutaneous (SC) administration.

DRUGPlacebo IV Infusion

Placebo administration via IV infusion.

Locations(2)

Altasciences LA

Cypress, California, United States

Altasciences Company Inc - Clinical Research Unit

Mount Royal, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07815561

Related Trials

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

NCT07798505

Phase 1 Study Involving SAB01 and Healthy Participants

Conditions

Summary

Eligibility

Plain Language Summary

Interventions

Locations(2)

Related Trials

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

The Effects of Oxytocin on Fairness Perception and Related Prosocial Behaviors

Phase 1 Study of ADX-626 in Healthy Participants

RIG 101 Trial in Healthy Adults and Adults With Asthma

Alpelisib Challenge Test (ACT)